Applied Therapeutics Completes Acquisition by Cycle Group; Shares to Delist from Nasdaq

summarizeSummary

Applied Therapeutics, Inc. has completed its acquisition by Cycle Group Holdings Limited for $0.088 cash per share plus a CVR, leading to its delisting from Nasdaq and cessation of public reporting.

check_boxKey Events

• Acquisition Completed

  Cycle Group Holdings Limited completed its acquisition of Applied Therapeutics, Inc. on February 3, 2026, following the expiration of its tender offer.

• Shareholder Consideration

  Shareholders will receive $0.088 in cash per share and one non-tradeable Contingent Value Right (CVR) per share, with potential future payments up to an aggregate of $0.40 per CVR.

• Delisting and Deregistration

  The company's common stock will be delisted from The Nasdaq Stock Market LLC, and Applied Therapeutics intends to terminate its SEC reporting obligations.

• Board and Officer Changes

  All previous directors and certain officers resigned, with James Harrison appointed as the sole director and President, and Andrea Reiner as Secretary.

auto_awesomeAnalysis

Applied Therapeutics, Inc. has finalized its acquisition by Cycle Group Holdings Limited, marking the end of its tenure as a publicly traded company. The merger, completed via a tender offer and subsequent short-form merger, results in shareholders receiving a cash payment of $0.088 per share plus a non-tradeable Contingent Value Right (CVR) with potential payments up to $0.40 per CVR. This transaction effectively removes the company's stock from Nasdaq and terminates its SEC reporting obligations, fundamentally altering the investment thesis. The low cash component of the offer, below the current stock price, combined with the non-tradeable and contingent nature of the CVR, suggests a challenging outcome for existing public shareholders.